Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.
Bone Marrow
/ pathology
Fusion Proteins, bcr-abl
/ genetics
Humans
Imidazoles
/ therapeutic use
Male
Middle Aged
Philadelphia Chromosome
Positron Emission Tomography Computed Tomography
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Protein Kinase Inhibitors
/ therapeutic use
Pyridazines
/ therapeutic use
Treatment Outcome
Philadelphia chromosome
Ponatinib
T-cell acute lymphoblastic leukemia
Journal
Acta haematologica
ISSN: 1421-9662
Titre abrégé: Acta Haematol
Pays: Switzerland
ID NLM: 0141053
Informations de publication
Date de publication:
Historique:
received:
14
12
2020
accepted:
17
03
2021
pubmed:
16
6
2021
medline:
15
12
2021
entrez:
15
6
2021
Statut:
ppublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is a rare entity in the adult acute leukemia setting. Translocation (9;22)(q34;q11) and BCR-ABL1 rearrangement are occasionally found in T-ALL and have been reported in no more than 100 cases in the literature (most of which are chronic myeloid leukemia blast crisis). Here, we report the remarkable effectiveness of third-generation tyrosine-kinase inhibitor ponatinib in obtaining hematological and metabolic remission, in a patient with Philadelphia chromosome-positive de novo T-ALL and outcomes of a therapeutic strategy containing chemotherapy intensification, nelarabine, and allogeneic hematopoietic stem cell transplantation.
Identifiants
pubmed: 34130278
pii: 000516003
doi: 10.1159/000516003
doi:
Substances chimiques
Imidazoles
0
Protein Kinase Inhibitors
0
Pyridazines
0
ponatinib
4340891KFS
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-692Informations de copyright
© 2021 S. Karger AG, Basel.